Institutional members access full text with Ovid®

Share this article on:

Selepressin in Septic Shock: A Step Toward Decatecholaminization?*

Asfar, Pierre MD, PhD; Russell, James A. MD, PhD; Tuckermann, Jan PhD; Radermacher, Peter MD, PhD

doi: 10.1097/CCM.0000000000001441
Editorials

Département de Réanimation Médicale et de Médecine Hyperbare, Centre Hospitalier Universitaire, Angers, France

Center for Heart Lung Innovation, Division of Critical Care Medicine, St. Paul’s Hospital, University of British Columbia, Vancouver, BC, Canada

Institut für Molekulare Endokrinologie der Tiere, Universität Ulm, Ulm, Germany

Institut für Anästhesiologische Pathophysiologie und Verfahrensentwicklung, Universitätsklinikum, Ulm, Germany

*See also p. 23.

Dr. Russell consulted for Ferring; received support for participation in review activities from Ferring (Data and Safety Monitoring Board membership); served as a board member for Cyon Therapeutics (no monetary payment to board); consulted for Cubist (now owned by Merck), Grifols, MedImmune, Leading Biosciences, La Jolla Pharmaceuticals, Cytovale, and Asahi Kesai; has patents with Cyon Therapeutics (PCSK9 and sepsis) and University of British Columbia (vasopressin in sepsis); and has stock in Cyon Therapeutics and Leading Biosciences. His institution received grant support from Grifols (contract under institutional review) and Ferring. Dr. Tuckermann’s institution received grant support from the German Research Council (Collaborative Research Centre [CRC] 1149) and the German Research Centre (Immunobone). Dr. Radermacher consulted for and received support for participation in review activities from Ferring Pharmaceuticals A/S (Copenhagen, Denmark). He received support for article research from the German Research Society (CRC 1149 “Danger Response, Disturbance Factors and Regenerative Potential after Acute Trauma”) and the Ferring Research Institute (San Diego, CA). He and his institution consulted for Boehringer Ingelheim Pharma GmbH & Co. KG (Biberach/Riss, Germany). His institution received grant support from Ferring Pharmaceuticals A/S, Ferring Research Institute, and Boehringer Ingelheim Pharma GmbH & Co. KG. Dr. Asfar has disclosed that he does not have any potential conflicts of interest.

Copyright © by 2016 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.